DuraSite 2 is expected to increase the tissue penetration for topically delivered ocular drugs and improve dosing convenience, according to the company.
The data published by the company also attributed superior drug retention and tissue penetration for DuraSite 2 as compared to DuraSite, an older version.
Based on InSite DuraSite technology, DuraSite 2 has a cationic polymer for sustained ocular drug delivery.
DuraSite 2 incorporates cataract surgery drug, ketorolac, a non-steroidal anti-inflammatory drug (NSAID).
InSite Vision Development vice president Lyle Bowman said with DuraSite 2, InSite has developed a new ophthalmic drug delivery platform to improve its technology.
"InSite scientists have unique expertise in formulating novel ophthalmic therapeutics, and we believe DuraSite 2 could be critical in optimizing the profile of approved and future ocular drugs, extending the drug retention on the eye and reducing dosing frequency and the amount of drug needed to achieve efficacious results,” Bowman.
”In addition to these potential clinical advantages, the intellectual property surrounding DuraSite 2 was filed in early 2009, providing potential patent life into 2029 for this new drug delivery system, as well as increased protection for all drugs formulated with DuraSite 2."